Launch of Generic Entresto (sacubitril/valsartan) Tablets

Generic Entresto (sacubitril/valsartan) has recently been approved by the FDA and released in 24mg/26mg, 49mg/51mg and 97mg/103mg dosage tablets.

Sacubitril/valsartan tablets are indicated to reduce the risk of cardiovascular death and hospitalization in adult patients with chronic heart failure and reduced ejection fraction, and for the treatment of symptomatic heart failure with systemic left ventricular systolic dysfunction in pediatric patients aged one year and older.

Several manufacturers will be releasing a generic formulation of Sacubitril/Valsartan tablets including Novadoz Pharmaceuticals, Camber, Ascend, and Macleods Pharma.

The post Launch of Generic Entresto (sacubitril/valsartan) Tablets appeared first on Carlisle Medical.